Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Sedative-Hypnotic or Stimulant or non-stimulant ADHD agent

Use the filters below to narrow your results.

generic:
brand:
None (51) · (none, never marketed) (1) · Benzedrex (1) · Dalmane (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Qelbree (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
GABAA positive allosteric modulator (15) · Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (72) · ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1)
starting dose:
None (72) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)
preparations:
None (72) · 100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
None (72) · 400 mg/d (pediatric); 600 mg/d (adult) (1) · N/A (never approved) (1)
routes:
None (72) · intranasal; rectal and IV reported. (1) · Oral (2) · sublingual (1)
onset:
None (72) · ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) · ~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (72) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Daily dosing (1)
halflife:
None (72) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~7 hours (1)
bioavailability:
None (72) · Adequate oral bioavailability with extended-release formulation (1) · Not formally characterized in humans. (1)
pregnancy:
None (72) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data (1)
legal:
None (73) · Rx, '''not a controlled substance''' (no DEA scheduling) (1)

Showing below up to 74 results in range #1 to #74.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"